Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 2 Apr 24 EFFECT Notice of effectiveness
- 26 Mar 24 POS AM Prospectus update (post-effective amendment)
- 18 Mar 24 424B3 Prospectus supplement
- 14 Mar 24 POS AM Prospectus update (post-effective amendment)
- 5 Mar 24 POS AM Prospectus update (post-effective amendment)
- 6 Feb 24 424B3 Prospectus supplement
- 8 Dec 23 424B3 Prospectus supplement
- 30 Nov 23 424B3 Prospectus supplement
- 21 Nov 23 EFFECT Notice of effectiveness
- 15 Nov 23 S-1/A IPO registration (amended)
- 10 Oct 23 S-1/A IPO registration (amended)
-
7 Aug 23 S-3 Shelf registration
SYRE similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of Aeglea BioTherapeutics, Inc. of our report dated March 2, 2023 relating to the financial statements, which appears in Aeglea BioTherapeutics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2022. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
August 7, 2023